NCT03075527 2026-01-08
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Dana-Farber Cancer Institute
Phase 2 Terminated
Clinical Trials
7 trialsNCT05380713 2025-12-29
......SMARTEST Trial......
University Health Network, Toronto
Phase 2 Completed
NCT05932199 2025-09-25
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
Baylor College of Medicine
Phase 1/2 Recruiting
NCT02592551 2022-09-29
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Baylor College of Medicine
Phase 2 Completed
NCT02588131 2015-10-27
A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)
Italian Network for Tumor Biotherapy Foundation
Phase 2 Unknown
NCT01655888 2012-08-02
The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma
Azienda Ospedaliera Universitaria Senese
Phase 2 Unknown
NCT01649024 2012-07-25
A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma
Azienda Ospedaliera Universitaria Senese
Phase 2 Unknown